- SEK457.99m
- SEK288.67m
- SEK180.16m
Brief: OssDsign Q1 Operating Loss At SEK 12.0 million
Brief: Ossdsign Awarded Long-Term Agreement With Premier, Inc.
Brief: OssDsign Q4 EPS at SEK -0.6
Brief: Ossdsign Expects Revenues For Q4, 2023 To Exceed Market Estimates
Brief: SEB Venture Capital Sells Its Holding In OssDsign
Brief: OssDsign Q3 Sales at SEK 31.7 Million
Brief: OssDsign Carries Out Directed Share Issue Of SEK 150 Mln
Brief: Ossdsign Announces Strategic Shift To Become A Pure Play Orthobiologics Company
Brief: Expanded FDA Market Approval For OssDsign Catalyst
Brief: OssDsign Q2 Sales at SEK 23.997 Million
Brief: OssDsign Q1 Net Income at SEK -23.3 Million
Brief: OssDsign Posts Q4 Loss Per Share of SEK 0.5
Brief: Karolinska Development's Ossdsign Presents Positive Long-Term Data For Ossdsign Cranial PSI
Brief: OssDsign Completes SEK 65.6 Mln Directed Share Issue
Brief: Ossdsign AB Intends To Carry Out A Directed New Share Issue
Brief: OssDsign Q3 Oper Loss Widens To SEK 19.6 Mln
Brief: OssDsign Q2 Loss After Tax Narrows To SEK 23.9 Mln
Brief: OssDsign Q1 Operating Loss Widens To SEK 24 Million
Brief: OssDsign Signs Agreement With France's Largest Hospital Network